The first day of the 2022 American Headache Society (AHS) Annual Scientific Meeting kicked off in Denver delivering interesting data and discussions. Click on the image above to view highlights from our team of analysts.
The first day of the 2022 American Headache Society (AHS) Annual Scientific Meeting kicked off in Denver delivering interesting data and discussions. Click on the image above to view highlights from our team of analysts.
The first day of the 2022 American Headache Society (AHS) Annual Scientific Meeting kicked off in Denver delivering interesting data and discussions. Click on the image above to view highlights from our team of analysts.
Cerebrovascular reactivity and deep white matter hyperintensities in migraine: A prospective CO 2 targeting study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35607990/
Several studies suggested the association of migraine with deep white matter hyperintensities (WMHs). We aimed to explore the cerebrovascular reactivity (CVR), deep WMH burden, and their association in patients with...
Relevance: Several studies suggested the association of migraine with deep white matter hyperintensities (WMHs). We aimed to explore the cerebrovascular reactivity (CVR), deep WMH burden, and their association in patients with migraine using a state-of-the-art methodology.
-
Huma Sheikh, CEO, NY Neurology Medicine, PC3yrThis is a concerning study since we do not know if these are silent infarcts?
Efficacy of ultrasound-guided greater occipital nerve pulsed radiofrequency therapy in chronic refractory migraine - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35650419/
In this study, we observed that US-guided GON PRF therapy applied at the proximal (C2) level was a safe and effective treatment option. With GON PRF, we observed a decrease...
Conclusion: In this study, we observed that US-guided GON PRF therapy applied at the proximal (C2) level was a safe and effective treatment option. With GON PRF, we observed a decrease in pain intensity, pain frequency, and duration of episodes, and an improvement in depression symptoms, migraine disability, and sleep disorder scores...
-
Huma Sheikh, CEO, NY Neurology Medicine, PC3yrI hope these studies help to make it possible for insurance companies to start covering these.
